Use of certain compounds in livestock food as growth promotants for better feed utilization and improved carcass composition

ABSTRACT

A method is described in which the feed utilization by livestock is improved by the incorporation in the feed or drinking water of the said livestock of certain compounds, with resultant increase in body weight, decrease in body fat and increase in body protein for the same food intake.

This application is a division of my copending application Ser. No.177,210, filed Apr. 4, 1988, now U.S. Pat. No. 4,847,302, which is adivision of Ser. No. 731,255 filed May 8, 1985, now U.S, Pat. No.4,761,421, issued Aug. 2, 1988, which is a continuation-in-part of Ser.No. 617,299, filed June 4, 1984 now abandoned.

STATEMENT OF THE INVENTION

This invention relates to a method of improving feed utilization andcarcass composition by livestock which comprises the incorporation inthe food or drinking water furnished to said livestock of from 0.01 to100 parts per million of at least one compound selected from the groupdescribed in Table A. More specifically, it comprises a method ofimproving feed utilization and carcass composition in which thecompounds of structures I, IV and IX are used. More specifically also,it relates to animal feed compositions for administration to livestockwhich comprises from 0.01 to 100 parts per million of a compound listedin Table A especially compounds I, IV and IX. The invention also relatesto ruminants as slow release rumen boluses releasing doses of from 0.1to 100 mg per head per day of at least one compound selected from thegroup listed in Table A especially compounds I, IV and IX. The inventionalso relates to all livestock as systemic implants that provide doses of0.001 to 10 mg per head per day.

                                      TABLE A                                     __________________________________________________________________________    I.   Zinterol                                                                               ##STR1##                                                        II.  Z 1170                                                                                 ##STR2##                                                        III. QH25B                                                                                  ##STR3##                                                        IV.  L-644,969                                                                              ##STR4##                                                        V.   Bitolterol                                                                             ##STR5##                                                        VI.  Reproterol                                                                             ##STR6##                                                        VII. Pirbuterol                                                                             ##STR7##                                                        VIII.                                                                              AA497                                                                                  ##STR8##                                                        IX.  Formoterol                                                                             ##STR9##                                                        __________________________________________________________________________

It will be appreciated by those skilled in the art that the abovecompounds have one or more asymmetric centers and may exist as separableoptical isomers or as equal mixtures of optical isomers which would beoptically inactive racemic mixtures. The foregoing structures arepresented in planar form, however, all possible optical isomerscontained therein are intended to be included within the ambit of thisinvention.

One skilled in the art will also realize that separated optical isomersmay often have different activities, one from the other, and suchdifferences are also to be considered within the instant invention.

As an example of this, it is noted that compound IV has two centers ofasymmetry, the first (referred to as "α") and third (referred to as "1")carbon atoms to the right of the pyridine ring carrying a hydroxy and amethyl substituent respectively. This will give rise to four possibleoptical isomers when the hydroxy and methyl are individually eitherabove (β) or below (α) the plane of the molecule. In particular theisomer wherein both the hydroxy and methyl are β (which is more exactlyreferred to as the α-R,1R compound) has been found to be significantlymore active than the most active of the other isomers.

BACKGROUND OF THE INVENTION

There is a need in animal husbandry for methods of improving theutilization of food. It is important not only that the growth of theanimals be promoted but that the utilization of the food be directed ina different way, namely, to produce less fat and more protein. Somecompounds have been described which enhance the utilization of food andchange the carcass composition in some species of food livestock. Bakeret al. have described (Fed. Proc. 42 No. 4 p. 816, No. 3 p. 668) that acompound called clenbuterol functions in this way. However, while thismay be the best such agent published in the scientific literature,clenbuterol is not as active as other compounds in poultry, sheep orswine, especially compared to the compounds used in this invention.

DESCRIPTION OF THE INVENTION

We have found that the compounds listed in Table A are highly active inpromoting the utilization of food by livestock intended for humanconsumption. They provide more growth and better utilization of the feedproducing more protein and less fat. As can be seen in Table A thecompounds involved differ widely in chemical structure. They also differdrastically from clenbuterol. While some of the active compounds listedin Table A are reported to have β-adrenergic activity, many compoundsreported to be β-adrenergic agonists have very little or no growthpromoting activity. Thus, accurate prediction of growth promotingactivity on the basis of chemical structure or β-adrenergic activity isnot possible.

Of a special use in this invention are the three compounds listed inTable A as I, IV and IX. All of these share high activity in all speciesunder consideration. However, all of these compounds of Table A enhancethe food utilization in some species by promoting growth and providingmore protein and less fat for the same food intake.

EXAMPLE 1 In Vitro Testing

Adipose tissue collection and preparation.

Fat was collected from freshly killed animals as follows: epididymal andperirenal fat from 150 to 200 g male rats; perirenal fat from 20 to 25kg wether lambs, and perirenal and omental fat from 35 to 50 kg gilts.Immediately after collection, fat was placed in a siliconized beaker(all glassware was siliconized) containing Krebs-Ringer bicarbonatesolution (KRB; pH 7.4) at 37° C. Fat was transferred to a clean beakerand finely chopped with scissors. Chopped fat was then used as such(whole adipose preparation) or treated with collagenase (isolatedadipocytes).

Isolation of adipocytes.

Chopped fat was placed in a shaker containing 70 ml cell dispersionmedium (CDM; 5 mM glucose, 0.1% collagenase, 4% bovine serum albumin(BSA), in KRB) and incubated at 37° C. for 1 hour with gentle shaking.Fat was then filtered to remove clumps and washed 4 times with washingmedium (WM; 2.5 mM glucose, 1% BSA, in KRB) and 1 time with finalsuspension medium (FSM; 2.5 mM glucose, 2% essentially fatty acid freeBSA, in KRB). Isolated adipocytes were then resuspended in the requiredamount of FSM (1 ml/flask, 3 flasks/treatment).

Determination of lipolytic activity in adipose tissue or adipocytes.

Whole adipose tissue from the rat (0.3 ml) or isolated adipocytes fromsheep or swine (1 ml) were placed in plastic scintillation vialscontaining FSM (1.7 or 1 ml, respectively) and test compounds, andincubated at 37° C. for 2 hours. Compounds were tested at concentrationsof 0.01, 0.05, 0.25 and 1.25 μM. Isoproterenol, at the sameconcentrations, was used as a positive control. After incubation, mediawas removed and assayed for glycerol by a fluorometric modification ofthe method of Wieland (1974. Glycerol UV-method. pp. 1404. In: Bergmeyer(Ed.) Methods of Enzymatic Analysis. Verlag Chemie Weinham, AcademicPress, New York).

Determination of anti-lipogenic activity in hepatocytes.

Hepatocytes were isolated from chicken liver using the procedure foradipocytes and incubated for 2 hours at 37° C. in the presence of ¹⁴ Cacetate and test compounds. Compounds were tested at concentrations of0.01, 0.05, 0.25 and 1.25 μM. Isoproterenol, at the same concentrations,was used as a positive control. After incubation, 8 ml Doles reagent(isopropanol:hexane:H₂ SO₄, 40:10:1) was added and incubation vials wereshaken at room temperature for 30 minutes. Vial contents were pouredinto 50 ml screw-cap tubes. Vials were then rinsed with 6 ml hexanewhich was poured into the appropriate 50 ml tube. Tubes were shaken byhand, 10 ml H₂ O was added, and tubes were shaken again. After phaseseparation, 2 ml of the upper (hexane) phase was removed toscintillation vials. Hexane was evaporated by a gentle air flow and theremaining lipids were resuspended in 10 ml Scinti Verse II. ¹⁴ C wascounted in a Packard liquid scintillation counter. Data are reported asCPM of ¹⁴ C acetate incorporated into total lipids.

Results of in vitro testing.

All nine compounds listed in Table A had significant antilipogenicactivity. The three compounds identified as I, IV and IX appear to havefive times the antilipogenic activity of isoproterenol and greater than125 times the antilipogenic activity of clenbuterol in chickenhepatocytes. The nine compounds were tested for lipolytic activity inisolated swine (Table C) and ovine (Table D) adipocytes. All ninecompounds significantly stimulated lipolysis in isolated swine or ovineadipocytes. Eight of the nine compounds were significantly more activethan clenbuterol in stimulating lipolysis in isolated adipocytes. Thelack of activity of clenbuterol in swine adipocytes should especially benoted.

The compounds were also tested (Table E) for lipolytic activity usingchopped adipose tissue from rats and all nine compounds were found to beactive. While rats are not a target species for the product, they are agood model for testing in vivo.

EXAMPLE 2 In Vivo Testing

Eighty intact, male Charles River CD rats, 75-90 g, were housed andmaintained on rat chow and water ad libitum. After four days acclimationten rats per group were randomized by weight to treatment and pen.Compounds to be tested were premixed and added to ground rat chow usingdoses equivalent to 20 ppm of clenbuterol on a molecular weight basis.It had previously been determined 10 ppm of clenbuterol was the minimumdose needed to give maximum improvements in gain and feed conversion.Therefore, the results of any compound tested should cause responsessimilar to clenbuterol if the compound has half or more the activity ofclenbuterol. The results are summarized in Table F and demonstrate thatall nine compounds listed in Table A are capable of improving rate ofgain and feed conversion and shifting carcass composition of growinganimals from fat toward protein.

                  TABLE B                                                         ______________________________________                                        Comparative Activity of Inhibitors of Lipogenesis by                          Isolated Chicken Hepatocytes                                                  (Measured by .sup.14 C acetate incorporation in fatty                         acids and expressed as percent change compared to                             control)                                                                              LEVEL μM                                                           COMPOUND  0.01      0.05     0.25    1.25                                     ______________________________________                                        Test 1                                                                        Isoproterenol                                                                           -29.1     -48.6    -70.3   -74.4                                    Clenbuterol                                                                             -4.2      -16.4    -24.6   -24.7                                    I         -45.2     -61.3    -66.0   -63.3                                    IV        -33.7     -54.3    -63.2   -65.1                                    IX        -50.5     -67.2    -72.3   -72.6                                    III       -9.5      -35.5    -54.4   -62.4                                    V         0         -34.0    -64.6   -68.8                                    VI        0         0        -8.6    -31.2                                    II        0         0        -7.9    -18.4                                    Test 2                                                                        Isoproterenol                                                                           -21       -15      -49     -61                                      Clenbuterol                                                                             -8        -18      -16     1                                        IX        -30       -56      -63     -64                                      VIII      26        -9       -34     -63                                      VI        3         -12      -25     -28                                      ______________________________________                                    

                  TABLE C                                                         ______________________________________                                        Comparative Activity of Stimulators of Lipolysis by                           Isolated Swine Adipocytes                                                     (Measured by glycerol production and                                          expressed as percent increase compared to                                     control)                                                                              LEVEL μM                                                           COMPOUND  0.01     0.05      0.25    1.25                                     ______________________________________                                        Test 1                                                                        Isoproterenol                                                                           40       140       660     333                                      Clenbuterol                                                                             27       -20       -27     -27                                      I         87       100       53      60                                       IV        260      333       80      53                                       IX        207      267       187     180                                      VIII      13       147       180     60                                       V         7        47        147     80                                       III       20       33        53      40                                       VI        20       -7        0       140                                      II        27       -7        -40     -27                                      Test 2                                                                        Isoproterenol                                                                           175      196       820     800                                      Clenbuterol                                                                             0        -20       4       17                                       IX        340      600       844     896                                      VIII      61       59        460     580                                      VI        8        21        3       160                                      ______________________________________                                    

                  TABLE D                                                         ______________________________________                                        Comparative Activity of Stimulators of Lipolysis by                           Isolated Ovine Adipocytes                                                     (Measured by glycerol production and                                          expressed as percent increase compared to                                     control)                                                                                LEVEL μM                                                         COMPOUND    0.01      0.05       0.25 1.25                                    ______________________________________                                        Test 1                                                                        Isoproterenol                                                                             670       1510       1820 2080                                    Clenbuterol inactive  240         325  305                                    I           730       960        1775 2400                                    IV          820       1160       1540 1645                                    IX          675       695        1525 2400                                    III         465       845        1775 2255                                    VIII        135       445        565   720                                    V           inactive  435        1170 2140                                    VI          inactive  130         465 2010                                    II          inactive  inactive    325  180                                    Test 2                                                                        Isoproterenol                                                                             600       1614       1800 2157                                    Clenbuterol 186       857        1171 1914                                    IX          2014      2100       2043 2271                                    VIII         71       1143       1800 2143                                    VI          -14       129         700 1800                                    ______________________________________                                          T1 TABLE E-Comparative Activity of Stimulators of Lipolysis by? -Rat     Adipose Tissue? -(Measured by glycerol production and? -expressed as     percent increase compared to? -control)? -LEVEL μM? -COMPOUND? 0.01?     0.05? 0.25? 1.25? -Test 1 ? ? ? ? -Isoproterenol 45 173 ? 290 272     -Clenbuterol 12 26  21  15 -I 90 129 ? 281 334 -IV 114 ? 219 ? 334 318 -IX     42 91 258 322 -V 17 33 111 288 -III 194 ? 203 ? 334 288 -VI 63 86  86 361     -II 51 15  35  91 -VIII 19 26  21  15 -Test 2 -Isoproterenol 49 154 ? 216     237 -Clenbuterol 10 10  16  43 -IX 16 70 145 222 -VI 13 16  13  46 -VIII     -7 ?  4  7  40? -

                                      TABLE F                                     __________________________________________________________________________    In vivo Testing in Rats                                                                           Feed                                                                              Feed  Carcass Composition                                         Weight                                                                            Gain                                                                              Intake                                                                            Conversion                                                                          % of Change over Control                        Compound                                                                              Dose                                                                              g   g/day                                                                             g/day                                                                             g/day Fat    Protein                                  __________________________________________________________________________    Test 1                                                                        Control  0  191.8                                                                             7.3 18.6                                                                              2.55  --     --                                       Clenbuterol                                                                           10  198.6                                                                             7.8 19.2                                                                              2.48  -11.3  11.2                                     VII     15.3 (a)                                                                          200.9                                                                             8.0 19.8                                                                              2.48   -8.7  3.6                                      V       38.5 (a)                                                                          192.2                                                                             7.3 18.7                                                                              2.58   -4.3  3.1                                      III     24.3 (a)                                                                          201.7                                                                             8.0 19.4                                                                              2.41   -7.0  6.1                                      I       26.4 (a)                                                                          199.1                                                                             7.8 19.2                                                                              2.46  -10.4  7.3                                      IX      21.8 (a)                                                                          199.4                                                                             7.9 19.1                                                                              2.44  -10.4  10.6                                     VIII    15.7 (a)                                                                          202.6                                                                             8.1 19.5                                                                              2.41   -6.1  6.4                                      Test 2                                                                        Control  0  202.3                                                                             7.5 19.3                                                                              2.63  --     --                                       Clenbuterol                                                                           10  216.9                                                                             8.2 19.9                                                                              2.46  -11.9  4.3                                      II      19.0 (a)                                                                          215.9                                                                             8.4 21.1                                                                              2.51   -9.3  3.8                                      VI      27.0 (a)                                                                          213.4                                                                             8.3 21.2                                                                              2.57     2.5 0.5                                      IV      23.0 (a)                                                                          214.7                                                                             8.4 20.7                                                                              2.48  -16.1  5.0                                      __________________________________________________________________________     (A) Dose based on molecular weight equivalent of 20 ppm clenbuterol.     

Dosage Utilization

The method of this invention is intended to increase the rate of bodyweight gain and/or feed efficiency and to decrease the carcass fat andincrease the carcass protein of livestock such as cattle, sheep,poultry, pigs, etc. The compounds described herein in Table A can beadministered in doses of from 0.01 to 100 ppm in feed or drinking water.In addition, they may be administered to ruminants as slow release rumenboluses at doses of 0.1 to 100 mg per head per day or to all livestockas systemic implants providing doses of 0.001 to 10 mg per head per day.The boluses and subcutaneous implants typically are designed to providefor continuous administration of the active growth promoting compoundfor about 100 days.

I claim:
 1. A method for improving the growth of livestock whichcomprises administering to such livestock a sufficient amount of acompound having the formula: ##STR10##